-
Product Insights
NewEpidermolysis Bullosa – Drugs In Development, 2024
Empower your strategies with our Epidermolysis Bullosa – Drugs In Development, 2024 report and make more profitable business decisions. Epidermolysis bullosa (EB) is a group of inherited bullous disorders characterized by blister formation in response to mechanical trauma. Symptoms include blistering of skin; deformity or loss of fingernails and toenails; internal blistering including on the throat, esophagus, upper airway, stomach, intestines, and urinary tract; skin thickening on palms and soles of the feet (hyperkeratosis); and scalp blistering, scarring, and hair loss...
-
Product Insights
NewVitiligo – Drugs In Development, 2024
Empower your strategies with our Vitiligo – Drugs In Development, 2024 report and make more profitable business decisions. Vitiligo is a condition in which skin loses melanin, the pigment that determines the color of skin, hair, and eyes. Symptoms include premature whitening or graying of the hair on teh scalp, eyelashes, eyebrows, or beard; loss of color in the tissues that line the inside of mouth; and loss of or change in color of the inner layer of eye. Treatment includes...
-
Product Insights
NewAndrogenic Alopecia – Drugs In Development, 2024
Empower your strategies with our Androgenic Alopecia – Drugs In Development, 2024 report and make more profitable business decisions. Androgenic alopecia, commonly known as male-pattern baldness or female-pattern hair loss, is a hereditary condition that leads to gradual hair thinning and eventual hair loss in a specific pattern. It is the most common type of hair loss and affects both men and women, although the presentation and progression may differ between the sexes. Androgenic alopecia is primarily influenced by genetic and...
-
Product Insights
NewPruritus – Drugs In Development, 2024
Empower your strategies with our Pruritus – Drugs In Development, 2024 report and make more profitable business decisions. Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch. Pruritus is caused by cancer, cancer treatments, infection, dry skin, and reactions to drugs. Symptoms include redness, bumps, spots or blisters, dry, cracked skin, and leathery or scaly texture to the skin. Risk factors include heat, allergies, asthma, hay fever, hives, and eczema. Treatment includes corticosteroids, antihistamines, and...
-
Product Insights
NewAlopecia – Drugs In Development, 2024
Empower your strategies with our Alopecia – Drugs In Development, 2024 report and make more profitable business decisions. Alopecia is the partial or complete loss of hair, especially on the scalp; it can occur in patches, on the entire head, or over the entire body. Thinning hair is the most obvious symptom. The predisposing factors include allergies, exposure to irritants or toxins, burns, injuries, and infections. The Alopecia drugs in development market research report provide comprehensive information on the therapeutics under...
-
Product Insights
NewMycoses – Drugs In Development, 2024
Empower your strategies with our Mycoses – Drugs In Development, 2024 report and make more profitable business decisions. Mycoses, also known as fungal infections, encompass a diverse group of diseases caused by fungi. These infections can affect various tissues in the body, including the skin, nails, and internal organs. Superficial mycoses, like athlete's foot and ringworm, involve the outer layers, while systemic mycoses can affect deeper tissues and may be more severe, particularly in individuals with weakened immune systems. Candidiasis is...
-
Company Insights
Almirall – Digital Transformation Strategies
Almirall 2023 Digital Transformation Strategies Report Overview Almirall is leveraging several emerging technologies to quickly discover drugs, drive sales, streamline production, expand market presence, and help patients recover quickly. Cloud, AI, and digital therapeutics are among the technologies the company is focusing on. The annual ICT spending of Almirall is estimated at $14.7 million for 2023. A major share of this spending is earmarked for software, ICT services, and hardware. Almirall is a global biopharmaceutical company specializing in dermatology. The...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALM-27134 in Autoimmune Disorders
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ALM-27134 in Autoimmune Disorders Drug Details:ALM-27134 is under development for the treatment of dermatological autoimmune diseases....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRX-3140 in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRX-3140 in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PRX-3140 in Alzheimer's Disease Drug Details:PRX-03140 (NTC-942) is under development for the treatment of Alzheimer's...